Myriad Genetics (MYGN) shares were down 7.5% in recent Wednesday trading after Scotiabank downgraded the stock to sector perform from sector outperform and adjusted its price target to $6 from $20.
Trading volume stood at over 970,000 shares compared with a daily average of about 1.9 million.
Price: 4.12, Change: -0.34, Percent Change: -7.53
免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。